Joo-Young Kim

List of Publications by Year
in descending order

70	1,727	257450 24	302126 39
papers	citations	h-index	g-index

71	71	71	2618
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Outcomes of intracranial germinomaâ€"A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies. Neuro-Oncology, 2022, 24, 1389-1399.	1.2	15
2	Oncologic outcomes according to the level of disease burden in patients with metachronous distant metastases from uterine cervical cancer: a Korean Radiation Oncology Group study (KROG 18-10). Journal of Gynecologic Oncology, 2022, 33, .	2.2	1
3	An Asian multi-national multi-institutional retrospective study comparing intracavitary versus the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical carcinoma. Journal of Radiation Research, 2022, 63, 412-427.	1.6	5
4	Active small bowel sparing in intracavitary brachytherapy for cervical cancer. Japanese Journal of Clinical Oncology, 2022, 52, 266-273.	1.3	0
5	Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years. Cancer Research and Treatment, 2021, 53, 378-388.	3.0	16
6	Definitive Chemoradiotherapy versus Radical Hysterectomy Followed by Tailored Adjuvant Therapy in Women with Early-Stage Cervical Cancer Presenting with Pelvic Lymph Node Metastasis on Pretreatment Evaluation: A Propensity Score Matching Analysis. Cancers, 2021, 13, 3703.	3.7	6
7	Why not de-intensification for uterine cervical cancer?. Gynecologic Oncology, 2021, 163, 105-109.	1.4	11
8	Neurocognitive and psychological functioning of pediatric brain tumor patients undergoing proton beam therapy for three different tumor types. Pediatric Blood and Cancer, 2021, , e29430.	1.5	3
9	Regression and pseudoprogression of pediatric optic pathway glioma in patients treated with proton beam therapy. Pediatric Blood and Cancer, 2021, 69, e29434.	1.5	4
10	Treatment outcome and long-term follow-up of central nervous system germ cell tumor using upfront chemotherapy with subsequent photon or proton radiation therapy: a single tertiary center experience of 127 patients. BMC Cancer, 2020, 20, 979.	2.6	10
11	Choosing Wisely, The Korean Perspective: The Launch of the Nationwide â€œRight Decision in Cancer Careâ€•Initiative. International Journal of Radiation Oncology Biology Physics, 2020, 107, 602-603.	0.8	2
12	Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea. International Journal of Gynecological Cancer, 2020, 30, 764-771.	2.5	4
13	Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer. Cancer Research and Treatment, 2020, 52, 396-405.	3.0	16
14	Choosing Wisely: The Korean Perspective and Launch of the â€˜Right Decision in Cancer Careâ€™ Initiative. Cancer Research and Treatment, 2020, 52, 655-660.	3.0	5
15	Upfront chemotherapy followed by response adaptive radiotherapy for intracranial germinoma: Prospective multicenter cohort study. Radiotherapy and Oncology, 2019, 138, 180-186.	0.6	18
16	The association of integration patterns of human papilloma virus and single nucleotide polymorphisms on immune- or DNA repair-related genes in cervical cancer patients. Scientific Reports, 2019, 9, 13132.	3.3	11
17	Protective association of HLA-DRB1*13:02, HLA-DRB1*04:06, and HLA-DQB1*06:04 alleles with cervical cancer in a Korean population. Human Immunology, 2019, 80, 107-111.	2.4	11
18	ZKSCAN3 Upregulation and Its Poor Clinical Outcome in Uterine Cervical Cancer. International Journal of Molecular Sciences, 2018, 19, 2859.	4.1	12

#	Article	IF	Citations
19	Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial. Gynecologic Oncology, 2018, 151, 39-45.	1.4	25
20	Risk prediction model for disease-free survival in women with early-stage cervical cancers following postoperative (chemo)radiotherapy. Tumori, 2018, 104, 105-110.	1.1	6
21	Clinical outcome of proton therapy for patients with chordomas. Radiation Oncology Journal, 2018, 36, 182-191.	1.5	12
22	Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea. Cancer Research and Treatment, 2018, 50, 335-344.	3.0	10
23	Central Nervous System Nongerminomatous Germ Cell Tumors. , 2018, , 275-292.		0
24	Integration Pattern of Human Papillomavirus Is a Strong Prognostic Factor for Disease-Free Survival After Radiation Therapy in Cervical Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 654-661.	0.8	12
25	Toxicities and doseâ€“volume histogram parameters of MRI-based brachytherapy for cervical cancer. Brachytherapy, 2017, 16, 116-125.	0.5	17
26	Variability in target delineation of cervical carcinoma: A Korean radiation oncology group study (KROG 15-06). PLoS ONE, 2017, 12, e0173476.	2.5	5
27	Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). Journal of Gynecologic Oncology, 2016, 27, e58.	2.2	11
28	Current status of brachytherapy in Korea: a national survey of radiation oncologists. Journal of Gynecologic Oncology, 2016, 27, e33.	2.2	15
29	Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). Journal of Gynecologic Oncology, 2016, 27, e17.	2.2	12
30	Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma. Cancer Research and Treatment, 2016, 48, 1074-1083.	3.0	2
31	Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial. Radiotherapy and Oncology, 2016, 120, 383-389.	0.6	23
32	Magnetic resonance image-guided brachytherapy for cervical cancer. Strahlentherapie Und Onkologie, 2016, 192, 922-930.	2.0	12
33	Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2. Annals of Clinical Biochemistry, 2016, 53, 561-567.	1.6	15
34	Postoperative Lower Extremity Edema in Patients with Primary Endometrial Cancer. Annals of Surgical Oncology, 2016, 23, 186-195.	1.5	29
35	Nucleotide Excision Repair Gene <i>ERCC2</i> and <i>ERCC5</i> Variants Increase Risk of Uterine Cervical Cancer. Cancer Research and Treatment, 2016, 48, 708-714.	3.0	12
36	Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors. Radiation Oncology, 2015, 10, 135.	2.7	32

#	Article	IF	Citations
37	Treatment of Retinoblastoma: The Role of External Beam Radiotherapy. Yonsei Medical Journal, 2015, 56, 1478.	2.2	41
38	A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17). Gynecologic Oncology, 2015, 138, 519-525.	1.4	4
39	Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. Acta OncolÃ³gica, 2015, 54, 1827-1832.	1.8	26
40	Understanding the Treatment Strategies of Intracranial Germ Cell Tumors: Focusing on Radiotherapy. Journal of Korean Neurosurgical Society, 2015, 57, 315.	1.2	34
41	Proton beam therapy reduces the incidence of acute haematological and gastrointestinal toxicities associated with craniospinal irradiation in pediatric brain tumors. Acta OncolÃ³gica, 2014, 53, 1158-1164.	1.8	45
42	Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: A multicenter retrospective study (KROG 13-10). Gynecologic Oncology, 2014, 132, 618-623.	1.4	88
43	A nomogram predicting the risks of distant metastasis following postoperative radiotherapy for uterine cervical carcinoma: A Korean radiation oncology group study (KROG 12-08). Radiotherapy and Oncology, 2014, 111, 437-441.	0.6	20
44	Physical Status of Human Papillomavirus Integration in Cervical Cancer Is Associated with Treatment Outcome of the Patients Treated with Radiotherapy. PLoS ONE, 2014, 9, e78995.	2.5	36
45	A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy. Radiation Oncology, 2013, 8, 28.	2.7	14
46	Retrospective analysis of treatment outcome of pediatric ependymomas in Korea: analysis of Korean multi-institutional data. Journal of Neuro-Oncology, 2013, 113, 39-48.	2.9	4
47	The size of the metastatic lymph node is an independent prognostic factor for the patients with cervical cancer treated by definitive radiotherapy. Radiotherapy and Oncology, 2013, 108, 168-173.	0.6	36
48	High Control Rate for Lymph Nodes in Cervical Cancer Treated with High-Dose Radiotherapy using Helical Tomotherapy. Technology in Cancer Research and Treatment, 2013, 12, 45-51.	1.9	13
49	Curative Chemoradiotherapy in Patients With Stage IVB Cervical Cancer Presenting With Paraortic and Left Supraclavicular Lymph Node Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 84, 741-747.	0.8	54
50	Outcomes and toxicities for the treatment of stage IVB cervical cancer. Archives of Gynecology and Obstetrics, 2012, 285, 1685-1693.	1.7	16
51	Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology. Journal of Gynecologic Oncology, 2011, 22, 32.	2.2	14
52	Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer. International Journal of Cancer, 2011, 129, 896-902.	5.1	28
53	Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. Journal of Cell Science, 2011, 124, 1077-1087.	2.0	111
54	Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiation Oncology, 2010, 5, 101.	2.7	35

#	Article	IF	Citations
55	Reply to M.-C. Vozenin et al. Journal of Clinical Oncology, 2010, 28, e342-e342.	1.6	2
56	Human papillomavirus 16 E6 increases the radiosensitivity of p53-mutated cervical cancer cells, associated with up-regulation of aurora A. International Journal of Radiation Biology, 2010, 86, 769-779.	1.8	18
57	3D CT-based high-dose-rate brachytherapy for cervical cancer: Clinical impact on late rectal bleeding and local control. Radiotherapy and Oncology, 2010, 97, 507-513.	0.6	116
58	Low Initial Human Papilloma Viral Load Implicates Worse Prognosis in Patients With Uterine Cervical Cancer Treated With Radiotherapy. Journal of Clinical Oncology, 2009, 27, 5088-5093.	1.6	54
59	Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine. Journal of Cancer Research and Clinical Oncology, 2008, 134, 397-404.	2.5	5
60	Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Human Pathology, 2008, 39, 1317-1322.	2.0	53
61	Computed Tomography-Based High-Dose-Rate Intracavitary Brachytherapy for Uterine Cervical Cancer: Preliminary Demonstration of Correlation Between Doseâ€“Volume Parameters and Rectal Mucosal Changes Observed by Flexible Sigmoidoscopy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1446-1454.	0.8	114
62	Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer. Cancer Science, 2007, 98, 329-333.	3.9	50
63	Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. Journal of Cancer Research and Clinical Oncology, 2006, 132, 302-308.	2.5	56
64	Pretreatment laparoscopic surgical staging in locally advanced cervical cancer: Preliminary results in Korea. Gynecologic Oncology, 2005, 97, 468-475.	1.4	38
65	Dosimetric parameters that predict late rectal complications after curative radiotherapy in patients with uterine cervical carcinoma. Cancer, 2005, 104, 1304-1311.	4.1	27
66	Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. European Journal of Cancer, 2005, 41, 2086-2092.	2.8	81
67	Use of the Rectal Retractor to Reduce the Rectal Dose in High Dose Rate Intracavitary Brachytherapy for a Carcinoma of the Uterine Cervix. Yonsei Medical Journal, 2004, 45, 113.	2.2	10
68	The bioreductive agent RH1 and Î³-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line. International Journal of Radiation Oncology Biology Physics, 2004, 58, 376-385.	0.8	19
69	Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation. Radiotherapy and Oncology, 2004, 70, 311-317.	0.6	6
70	Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma. Cancer Research and Treatment, 1970, 47, 34-45.	3.0	54